CDK4/6 inhibitors in luminal breast cancer. (Q54301108)

27 May 2018

title

CDK4/6 inhibitors in luminal breast cancer. (English)

1 reference

27 May 2018

author

Michael Gnant

series ordinal

1

1 reference

27 May 2018

author name string

Guenther G Steger

series ordinal

2

1 reference

27 May 2018

Rupert Bartsch

series ordinal

3

1 reference

27 May 2018

publication date

16 December 2014

1 reference

27 May 2018

Lancet Oncology Commission

published in

1 reference

27 May 2018

volume

16

1 reference

27 May 2018

issue

1

1 reference

27 May 2018

page(s)

2-3

1 reference

27 May 2018

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Cell cycle control in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71188-X

7 January 2021

10.1016/S1470-2045(14)71188-X

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018